Lantheus Holdings, Inc. (NASDAQ:LNTH) Receives Consensus Rating of “Moderate Buy” from Brokerages

Shares of Lantheus Holdings, Inc. (NASDAQ:LNTH) have been assigned a consensus recommendation of “Moderate Buy” from the eleven analysts that are currently covering the firm, Marketbeat reports. Three research analysts have rated the stock with a hold rating and eight have issued a buy rating on the company. The average 12-month target price among analysts that have issued a report on the stock in the last year is $110.4286.

Several research analysts have recently commented on LNTH shares. Truist Financial boosted their price objective on Lantheus from $115.00 to $125.00 and gave the stock a “buy” rating in a report on Thursday. Weiss Ratings reiterated a “hold (c)” rating on shares of Lantheus in a research report on Tuesday, May 26th. The Goldman Sachs Group reissued a “neutral” rating and issued a $94.00 price target on shares of Lantheus in a research note on Thursday, May 7th. B. Riley Financial increased their price target on shares of Lantheus from $97.00 to $129.00 and gave the stock a “buy” rating in a report on Thursday, July 9th. Finally, Mizuho raised their price objective on shares of Lantheus from $115.00 to $120.00 and gave the company a “market outperform” rating in a research report on Wednesday.

Institutional Trading of Lantheus

A number of hedge funds have recently bought and sold shares of the company. CWA Asset Management Group LLC purchased a new stake in shares of Lantheus during the fourth quarter valued at approximately $1,670,000. Versor Investments LP bought a new position in Lantheus during the 4th quarter valued at approximately $519,000. M&T Bank Corp bought a new position in Lantheus during the 4th quarter valued at approximately $539,000. Bleakley Financial Group LLC purchased a new stake in Lantheus in the 4th quarter worth approximately $771,000. Finally, Sector Gamma AS lifted its holdings in Lantheus by 45.7% in the 4th quarter. Sector Gamma AS now owns 93,823 shares of the medical equipment provider’s stock worth $6,244,000 after buying an additional 29,420 shares during the period. Institutional investors own 99.06% of the company’s stock.

Lantheus Trading Up 2.4%

Shares of Lantheus stock opened at $107.59 on Friday. The company’s 50-day moving average price is $102.40 and its 200-day moving average price is $84.23. The company has a current ratio of 2.83, a quick ratio of 2.64 and a debt-to-equity ratio of 0.47. Lantheus has a 12-month low of $47.25 and a 12-month high of $111.86. The company has a market cap of $7.00 billion, a price-to-earnings ratio of 25.93 and a beta of -0.06.

Lantheus (NASDAQ:LNTH) last posted its earnings results on Thursday, May 7th. The medical equipment provider reported $1.46 earnings per share for the quarter, topping analysts’ consensus estimates of $1.25 by $0.21. The business had revenue of $377.33 million for the quarter, compared to analyst estimates of $354.48 million. Lantheus had a net margin of 18.05% and a return on equity of 29.32%. Lantheus’s revenue was up 1.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted $1.53 EPS. Lantheus has set its FY 2026 guidance at 5.000-5.250 EPS. On average, equities analysts expect that Lantheus will post 4.5 earnings per share for the current fiscal year.

About Lantheus

Lantheus Holdings, Inc is a global life sciences company specializing in the development, manufacturing and commercialization of diagnostic imaging agents and radiopharmaceuticals. Headquartered in North Billerica, Massachusetts, Lantheus focuses on products that enhance the detection and management of cardiovascular and oncologic diseases. The company’s portfolio spans ultrasound-enhancing agents, molecular imaging tracers for positron emission tomography (PET), and emerging theranostic platforms designed to pair diagnostic and therapeutic applications.

The diagnostic imaging segment includes ultrasound contrast agents such as DEFINITY® (perflutren lipid microsphere) and Sonazoid® (perflubutane), which improve the visualization of cardiac structures and blood flow.